Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.

Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.

Item
http://www.wikidata.org/entity/Q31016134
Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trialsGetting the balance right: Established and emerging therapies for major depressive disordersSafety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials.A systematic review of duloxetine and venlafaxine in major depression, including unpublished data.Rescue pharmacotherapy with duloxetine for selective serotonin reuptake inhibitor nonresponders in late-life depression: outcome and tolerability.Frequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational study.The effect of initial duloxetine dosing strategy on nausea in korean patients with major depressive disorderAdverse reactions to duloxetine in depression.An Open-Label Pilot Study of Combined Augmentation With Creatine Monohydrate and 5-Hydroxytryptophan for Selective Serotonin Reuptake Inhibitor- or Serotonin-Norepinephrine Reuptake Inhibitor-Resistant Depression in Adult Women.Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study.Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels.Switching to duloxetine from selective serotonin reuptake inhibitors in non- or partial responders: Results from a Spanish sample.Asymmetric synthesis of duloxetine intermediate (S)-(-)-3-N-methylamino-1-(2-thienyl)-1-propanol using immobilized Saccharomyces cerevisiae in liquid-core sodium alginate/chitosan/sodium alginate microcapsules.A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease.Tolerability aspects in duloxetine-treated patients with depression: Should one use a lower starting dose in clinical practice?A rapid and sensitive liquid chromatography-tandem mass spectrometric assay for duloxetine in human plasma: Its pharmacokinetic application.Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil
P2860

Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.

Item
http://www.wikidata.org/entity/Q31016134
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Duloxetine for the treatment o ...... cross the approved dose range.
@ast
Duloxetine for the treatment o ...... cross the approved dose range.
@en
type
label
Duloxetine for the treatment o ...... cross the approved dose range.
@ast
Duloxetine for the treatment o ...... cross the approved dose range.
@en
prefLabel
Duloxetine for the treatment o ...... cross the approved dose range.
@ast
Duloxetine for the treatment o ...... cross the approved dose range.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Duloxetine for the treatment o ...... cross the approved dose range.
@en
P2093
P304
P31
P356
10.1016/J.JPSYCHIRES.2005.08.010
P433
P478
P577
P698